Evaluation of the effect of melatonin with N-acetylcysteine in reducing liver injury caused by Remdesivir injection

The effect of melatonin with N-acetylcysteine in reducing liver injury caused by Remdesivir injection in Covid 19 patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210926052586N2

Enrollment

Registered

2022-02-26

Start date

2022-02-27

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver injury. Unspecified injury of liver, initial encounter

Interventions

Intervention group: During hospitalization, 6 mg of melatonin before bed and 600 mg of N acetylcysteine.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Hospitalization indication of Covid 19 patient Indication for Remdesivir injection Patient satisfaction to participate in this research project Patients over 18 years old

Exclusion criteria

Exclusion criteria: Presence of underlying liver disease in the patient Inability to receive oral drug

Design outcomes

Primary

Measure	Time frame
The effect of melatonin with N-acetylcysteine in reducing liver injury caused by Remdesivir injection. Timepoint: From the time of hospitalization serially until discharge. Method of measurement: Liver enzymes for aspartate aminotransferase , alanine aminotransferase and Alkaline phosphatase from blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedmohammad Karimi

Artesh University of Medical Sciences

smkarimi.md@gmail.com+98 21 8609 6350

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026